Evaluation of efficacy of bevacizumab combined with coelom hyperthermia perfusion on serum malignant biological indexes in patients withendometrial carcinoma(EC)
Objective To analyze the effect of bevacizumab combined with coelom hyperthermia perfusion on endometrial carcinoma(EC)and its influence on serum malignant biological indexes.Methods 89 EC patients,admitted between January 2018 and January 2020,were selected and divided into control group(44 patients)and study group(45 patients)by random number table method.The control group received coelom hyperthermia perfusion.The study group used bevacizumab combined with intraperitoneal ther-moperfusion chemotherapy.The chemotherapy effect of the 2 groups was compared.Serum malignant bi-ological indexes,proto-oncogene expression,occurrence of adverse reactions and prognosis before and after thechemotherapy.Results Comparison of effective rate and disease control rate after chemotherapy was higher in the study group than in the control group(P＜0.05).The serum levels of malignant tumour-specific growth factor(TSGF),prolactin(PRL),vascular endothelial growth factor(VEGF)and carbo-hydrate antigen 125(CA125)wasdecreased in both groups after the chemotherapy(P＜0.05),and the above serum malignant biological indexes were lower in the study group than in the control group after the chemotherapy(P＜0.05).The mRNA expression levels of proto-oncogene human epidermal growth fac-tor receptor 2(c-erbB2),MYC oncogene(c-myc)and Kirsten ratsarcoma viral oncogene homolog(K-ras)wasdecreased after chemotherapy in both groups(P＜0.05).The expression levels of c-erbB 2,c-myc and K-ras in the study group after thechemotherapy were lower than those in the control group(P＜0.05).There was no statistically significant difference in the incidence of toxic side effects between the 2 groups(P＞0.05).During the follow-up period of 6 to 36 months,the pogression-free survival of control group and the study group were 47.70％and 68.20％,the median survival time of progression-free was 10 months and 16 months,the overall survival rate was 20.5％and 42.20％,and the median survival time of overall survival was 18 months and 23 months,respectively.The progression-free survival curve(Log-Rank=7.404,P=0.007)and overall survival curve were significantly different between the 2 groups(Log-Rank=8.432,P=0.004).Conclusion Bevacizumab combined with coelom hyperthermia perfusion has a significant effect on EC patients,which can effectively reduce the level of serum malignant biological indicators and proto-oncogenes,prolong the survival time of patients with good safety.
bevacizumabcoelom hyperthermia perfusionendometrial cancer(EC)tumor specific growth factor(TSGF)prolactinvascular endothelial growth factor(VEGF)
NETL
NSTL
万方数据
